NCT05736835 - A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults | Biotech Hunter

Enrollment

227

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions

COVID-19

Interventions

BIOLOGICAL

CVXGA

CVXGA is a live viral vector, consisting of a recombinant parainfluenza virus type 5 that carries the SARS-CoV-2 S-protein from WA.1 (not enrolling) or XBB1.5 strain.

Trial Locations (10)

13850

Velocity Clinical Research, Vestal

14642

University of Rochester, Rochester

20854

Velocity Clinical Research, Rockville

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

51106

Velocity Clinical Research, Sioux City

68134

Velocity Clinical Research, Omaha

78759

Velocity Clinical Research, Cedar Park

83642

Velocity Clinical Research, Boise

91942

Velocity Clinical Research, San Diego

02818

Velocity Clinical Research, Providence